BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32558711)

  • 1. 10-Year Clinical Experience With 18F-Choline PET/CT: An Italian Multicenter Retrospective Assessment of 3343 Patients.
    Zattoni F; Ravelli I; Rensi M; Capobianco D; Borsatti E; Baresic T; Chiaravalloti A; Schillaci O; Alongi P; Bartolotta TV; Rambaldi I; Bartolomei M; Farsad M; Tredici M; Donner D; Chierichetti F; Trifirò G; Brugola E; Burei M; Dal Moro F; Cecchin D; Evangelista L
    Clin Nucl Med; 2020 Aug; 45(8):594-603. PubMed ID: 32558711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (11)C-Choline PET/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series.
    Graziani T; Ceci F; Castellucci P; Polverari G; Lima GM; Lodi F; Morganti AG; Ardizzoni A; Schiavina R; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1971-9. PubMed ID: 27277279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
    J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performance of
    Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early biochemical relapse after radical prostatectomy: which prostate cancer patients may benefit from a restaging 11C-Choline PET/CT scan before salvage radiation therapy?
    Castellucci P; Ceci F; Graziani T; Schiavina R; Brunocilla E; Mazzarotto R; Pettinato C; Celli M; Lodi F; Fanti S
    J Nucl Med; 2014 Sep; 55(9):1424-9. PubMed ID: 24935990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Michaud L; Touijer KA; Mauguen A; Zelefsky MJ; Morris MJ; Lyashschenko SK; Durack JC; Humm JL; Weber WA; Schöder H
    J Nucl Med; 2020 Jun; 61(6):827-833. PubMed ID: 31862801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of recurrent prostate cancer with PET/CT imaging using the gastrin-releasing peptide receptor antagonist
    Wieser G; Popp I; Christian Rischke H; Drendel V; Grosu AL; Bartholomä M; Weber WA; Mansi R; Wetterauer U; Schultze-Seemann W; Meyer PT; Jilg CA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1463-1472. PubMed ID: 28417160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer.
    Picchio M; Briganti A; Fanti S; Heidenreich A; Krause BJ; Messa C; Montorsi F; Reske SN; Thalmann GN
    Eur Urol; 2011 Jan; 59(1):51-60. PubMed ID: 20869161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection rate of 18F-Choline positron emission tomography/computed tomography in patients with non-metastatic hormone sensitive and castrate resistant prostate cancer.
    Zattoni F; Artioli P; Burei M; Chiaravalloti A; Chierichetti F; Donner D; Panareo S; Rambaldi I; Schillaci O; Dal Moro F; Evangelista L
    Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):167-173. PubMed ID: 34477346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy.
    Giovacchini G; Picchio M; Coradeschi E; Bettinardi V; Gianolli L; Scattoni V; Cozzarini C; Di Muzio N; Rigatti P; Fazio F; Messa C
    Eur J Nucl Med Mol Imaging; 2010 Feb; 37(2):301-9. PubMed ID: 19756592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?
    Heinisch M; Dirisamer A; Loidl W; Stoiber F; Gruy B; Haim S; Langsteger W
    Mol Imaging Biol; 2006; 8(1):43-8. PubMed ID: 16315004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of ¹⁸F-choline PET/CT in suspicion of relapse following definitive radiotherapy for prostate cancer.
    Chondrogiannis S; Marzola MC; Ferretti A; Maffione AM; Rampin L; Grassetto G; Nanni C; Colletti PM; Rubello D
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1356-64. PubMed ID: 23670521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mediastinal lymph node uptake in patients with prostate carcinoma on F18-choline PET/CT.
    Rietbergen DD; van der Hiel B; Vogel W; Stokkel MP
    Nucl Med Commun; 2011 Dec; 32(12):1143-7. PubMed ID: 22045476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Real-world" evaluation of
    Niziers V; Boissier R; Borchiellini D; Deville JL; Khoury C; Durand M; Toledano H; Albert T; Branger N; Bandelier Q; Ouvrier MJ; Gabriel S; Hoch B; Gross E; Walz J; Brenot-Rossi I; Pignot G
    Urol Oncol; 2020 Jan; 38(1):2.e1-2.e9. PubMed ID: 31447087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.